Investors Alert on H.J. Heinz Company (NYSE:HNZ), General Mills, Inc. (NYSE:GIS), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Pharmacyclics, Inc. (NASDAQ:PCYC)

New York, NY -- (SBWIRE) -- 02/22/2013 -- H.J. Heinz Company (NYSE:HNZ) reported higher-than-expected quarterly earnings on Thursday, assisted by strength in developing markets. Net income was $269.5 million, or 83 cents per share, in the quarter, down from $284.7 million, or 88 cents per share, a year prior. Sales soared some 18 percent in growing markets, which represented 23 percent of total company sales.

In the last trading session, H.J. Heinz Company (NYSE:HNZ) jumped +0.07% and closed at $72.19 with the overall traded volume of 7.34 million shares. HNZ has market cap of 23.15 billion.

Will HNZ Continue To Move Higher? Find Out Here

General Mills, Inc. (NYSE:GIS) confirmed its earnings guidance for the fiscal year ending May 26, 2013, of $2.65 to $2.67 per share, before certain items affecting comparability. The company also screened its fiscal 2014 plans, which comprise stronger EPS growth and augmented cash returns to shareholders.

In the last trading session, General Mills, Inc. (NYSE:GIS) dropped -0.31% and closed at $45.33 with the total traded volume of 3.93 million shares. Stock price 52 weeks high was $45.73 and 52 weeks low price was $36.75.

Is it the Right to Grab GIS after the Recent Slump? Get Free Trend Analysis Here

Celldex Therapeutics, Inc. (NASDAQ:CLDX) surged +3.25% with the closing price of $9.20. The overall volume in the last trading session was 1.65 million shares. Its fifty two week range was $3.52-$9.28. The total market capitalization remained $570.17 million.

CLDX is ahead its 52 week low with 161.36% and its last month price volatility remained 5.54%. Its beta coefficient was 1.89 with a target price of $11.29. In its share capital CLDX has 80.60 million outstanding shares while 80.38 million shares have been floated in market. CLDX has insider ownership of 0.37% with its institutional ownership remained 50.35%.

For How Long CLDX’s Gloss will Attract Investors? Find out via this report

Pharmacyclics, Inc. (NASDAQ:PCYC) reported second quarter adjusted EPS of $0.62 after the close Thursday, above than the analysts estimates but down from $0.82 in the prior year period. The consensus estimate was for EPS of $0.29.

Pharmacyclics, Inc. (NASDAQ:PCYC) surged +4.38% and closed at $88.81 in the last trading session with the total traded volume of 1.08 million shares.

What was the Moving Force behind PCYC On Bullish Run? Read This Research Report

About Alpha Penny Stock
Alphapennystock.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “penny stocks”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. We strive to live up to our name, Alpha, being the leader in the industry. It is important to understand that these stocks also carry high risk. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.

We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.